Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026
Basics
Sector
Healthcare
Industry
Healthcare Plans
Country
United States
Market cap
78.1B USD
Enterprise value
104.5B USD
Full-time employees
65,669
Overall health
Drawback:higher risk than most peers: less short-term liquidity (current ratio 0.85 vs a peer median of 2.59) and more debt relative to equity (0.75× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 0.85 vs peers 2.59) and more debt vs equity (0.75× vs peers 0.22×)
About average: profitability
Ranks #372 of 1,157 healthcare companies (top 33%)
Valuation signals disagree. Cheaper than 91% of peers on earnings, but only 50% on free cash flow.
Relative to its earnings, Cigna looks cheaper than 91% of peers; relative to its free cash flow, cheaper than only 50%. The valuation score blends the two, so look at which measure fits this business best.
Sales growing faster than profits. Since 2022: revenue +52%, operating profit +8.9%.
Since 2022, Cigna's revenue changed +52% but operating profit only +8.9%: costs are rising faster than sales.
Share count shrinking. Shares outstanding down 12% from December 2022 to July 2026.
Cigna had 12% fewer shares at July 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $160.4B in 2020 to $274.9B in 2025.
Cigna's fiscal-year revenue rose in each of the five years to 2025, from $160.4B to $274.9B.
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Oct 27, 2026 close: Score 88 → 89
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Cigna
Is Cigna getting weaker?
Its latest SEC filing (Jul 30, 2026) showed no major changes. Its overall score is unchanged at 60/100 since Oct 28, 2026.
How is Cigna valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 89/100 against 1,393 healthcare peers.Earnings yield 8.2% vs a peer median of 1.5% (stronger than 91% of peers).Earnings yield 8.2% vs peers 1.5% (stronger than 91% of peers).
Is Cigna growing?
Yes, faster than most of its peers. Growth scores 64/100 against 1,393 healthcare peers.Earnings per share growth 33.0% vs a peer median of 9.8% (stronger than 75% of peers).Earnings per share growth 33.0% vs peers 9.8% (stronger than 75% of peers).
How profitable is Cigna?
About as profitable as its peers. Profitability scores 59/100 against 1,393 healthcare peers.Return on invested capital 11.5% vs a peer median of 4.7% (stronger than 72% of peers).Return on invested capital 11.5% vs peers 4.7% (stronger than 72% of peers).
How risky is Cigna?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 0.30 vs a peer median of 0.63 (stronger than 79% of peers).Beta 0.30 vs peers 0.63 (stronger than 79% of peers).Current ratio 0.85× vs a peer median of 2.59× (weaker than 94% of peers).Current ratio 0.85× vs peers 2.59× (weaker than 94% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
277.9B USD
282.4B USD
+1.6%
Net income (12 months)
6.3B USD
6.4B USD
+2.0%
Operating margin
3.4%
3.5%
+0.1 pts
Debt
30.9B USD
31.9B USD
+3.2%
Cash
7.0B USD
6.3B USD
−10.5%
Shares outstanding
264.5M
264.2M
−0.1%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Healthcare Plans companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
4.6%
4.7%
4.4%
3.8%
3.3%
▼ 0.5 pts
Net margin
3.1%
3.8%
2.6%
1.4%
2.2%
▲ 0.8 pts
Return on assets (ROA)
3.5%
4.7%
3.4%
2.2%
3.8%
▲ 1.6 pts
Return on equity (ROE)
11.5%
15.2%
11.2%
8.4%
14.3%
▲ 5.9 pts
Debt to equity
0.71×
0.70×
0.67×
0.78×
0.75×
▼ 3.2%
Interest coverage
6.11×
6.50×
6.10×
6.28×
6.57×
▲ 4.7%
CI price history
Price history is added with the daily price update and will appear after the next one.